Nasdaq apls.

The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14.The new research reports from Market Source Research, available for free download at the links above, examine Fibrocell Science Inc (NASDAQ:FCSC), Sears Hometown and Outlet Stores, Inc. (NASDAQ ...NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Apellis Pharmaceuticals (NASDAQ:APLS) dropped 10% amid a new short report. The short report is apparently from Favus research, according to traders on Wednesday. Details of the short report couldn ...

We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...

value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ...

Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a report by Citron Research casting doubts on the company's prospects and the safety of its recently approved treatment for ...Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ...CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals...

Nov 20, 2023 · Shares of NASDAQ APLS opened at $49.10 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -9.35 and a beta of 0.97. The company has a current ratio of 4.29, a quick ratio of 3.76 and a debt-to-equity ratio of 0.40. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75.

APLS Quantitative Stock Analysis. June 27, 2023 — 12:04 pm EDT. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for APELLIS PHARMACEUTICALS INC ( APLS). Of the ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information. Instantly APLS has showed a red trend with a performance of -2.34% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 50.19 on Tuesday, 11/28/23 increased the stock’s daily price by 6.04%.WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a grant ...Jan 31, 2018 · Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results. APLS Latest Pre Market Trades About Latest Pre-Market Trades Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq …Apellis Pharmaceuticals (NASDAQ:APLS) Insider Buying and Selling Activity. Current Insider Ownership Percentage 7.50%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 13. Amount Of Insider Selling (Last 12 Months) $35.44 M. Get APLS Insider Trade Alerts. Want to know when executives …

9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...... Pharmaceuticals (NASDAQ: APLS). Wedbush Analyst forecast on APLS. Laura ChicoWedbush. 08/29/23. $29.00. Hold. -40.94%. Downside. Reiterated. Follow. 0. 0.See historical performance and comparison. View Valuation. Research Apellis Pharmaceuticals' (Nasdaq:APLS) stock price, latest news & stock analysis. Find …The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company.WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...On October 12, 2023, Brian Cheng, an analyst at BofA Securities, expressed his viewpoint on Apellis Pharmaceuticals (NASDAQ:APLS). Despite maintaining a Neutral rating, Cheng increased the price target for the company from $44 to $46. It is worth noting that Apellis Pharmaceuticals has garnered a Strong Buy consensus among analysts, who have set a …

On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...

For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.WALTHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the ...WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.With a volume of 1,248,030, the price of APLS is up 1.39% at $51.0. RSI indicators hint that the underlying stock may be approaching overbought. Next earnings are expected to be released in 82 days.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved t...Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Feb 21, 2023 · WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights.

Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ...

Dec 1, 2023 · How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.

Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Apellis Pharmaceuticals (NASDAQ:APLS) Insider Buying and Selling Activity. Current Insider Ownership Percentage 7.50%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 13. Amount Of Insider Selling (Last 12 Months) $35.44 M. Get APLS Insider Trade Alerts. Want to know when executives …9 de set. de 2023 ... Fintel reports that on September 8, 2023, B of A Securities maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...Find the latest analyst research for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...

(APLS) Share Price. NASDAQ. $49.10. As on 17-Nov-2023 16:00 EST. up-down-arrow $1.21 • 2.53%. Prev Close info. $47.89. Day's Open info. $47.74. Today's High ...The new research reports from Market Source Research, available for free download at the links above, examine Fibrocell Science Inc (NASDAQ:FCSC), Sears Hometown and Outlet Stores, Inc. (NASDAQ ...WALTHAM, Mass. and NANTES, France, June 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc (Nasdaq: APLS) and Affilogic today announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins® targeting …Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM.Instagram:https://instagram. equity multiple reviewhdge etfmichael jordan autographedgoogle stock predictions Apellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ... small stocksbest paper money trading platform Nov 30, 2023 · The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ... WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights. best trading course NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. San Diego, CA -- (SBWIRE) -- 11/14/2023 -- Certain directors of Apellis Pharmaceuticals, Inc. are under investigation on behalf of current long-term investors in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) concerning potential …How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.